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Abstract:  
 
Blood chimerism has been reported sporadically among visceral transplant 
recipients, mostly in association with graft-vs-host disease (GVHD). We 
hypothesized that a higher degree of mixed chimerism would be observed in 
multivisceral (MVTx) than in isolated intestinal (iITx) and isolated liver transplant 
(iLTx) recipients, regardless of GVHD. We performed a longitudinal prospective 
study investigating multilineage blood chimerism with flow cytometry in 5 iITx and 
4 MVTx recipients up to one year post-transplant. Although only one iITx patient 
experienced GVHD, T-cell mixed chimerism was detected in 8 out of 9 iITx/MVTx 
recipients. Chimerism was significantly lower in the four subjects who displayed 
early moderate to severe rejection. Pre-formed high titer donor-specific 
antibodies, bound in vivo to the circulating donor cells, were associated with an 
accelerated decline in chimerism. Blood chimerism was also studied in 10 iLTx 
controls. Among non-sensitized patients, MVTx recipients exhibited greater T 
and B-cell chimerism than either iITx and iLTx recipients. Myeloid lineage 
chimerism was present exclusively among iLTx and MVTx (6/13) recipients, 
suggesting that its presence required the hepatic allograft. Our study 
demonstrates, for the first time, frequent T cell chimerism without GVHD 
following visceral transplantation and a possible relationship with reduced 
rejection rate in MVTx recipients. 
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Introduction  
 
The concept of chimerism, the co-existence of donor and recipient hematopoietic 
elements, has captivated immunologists for over sixty years. Microchimerism 
(denoting <1% donor cells in this manuscript) is known to occur among solid 
organ transplant (SOT) recipients in the immediate post-operative period and has 
likewise been documented in some long-term transplant survivors, leading to 
speculation about its role in promoting tolerance (1). The mechanism behind the 
development of chimerism among SOT recipients is thought to be associated 
with the transfer of so-called “passenger lymphocytes” carried to the host within 
the transplanted donor tissue (1, 2).  Several groups have investigated the role of 
microchimerism in facilitating allograft acceptance (3, 4), but failed to 
demonstrate that microchimerism was sufficient for tolerance induction in either 
animals or humans (5). However, in both animal studies and pilot clinical trials, 
we and others have demonstrated that durable or transient macrochimerism 
(≥1% donor cells) can be achieved without Graft-Versus-Host Disease (GVHD) 
and can lead to donor specific-tolerance (6-8). While these trials relied on 
myelosuppressive pre-treatment followed by bone marrow infusion, other studies 
of human SOT recipients have involved administration of donor bone marrow 
without myelosuppressive conditioning to promote engraftment. To date, none 
have been associated with successful immunosuppression withdrawal (9). 
The spontaneous development of macrochimerism, or mixed chimerism after 
organ transplantation has been less extensively studied. Individuals who receive 
 6 
densely lymphoid allografts, including liver, intestinal and multivisceral 
transplants, demonstrate a higher incidence of GVHD compared to recipients of 
other organs (10, 11). Studies of macrochimerism have largely focused on its 
potential role as a biomarker for the development of this life-threatening 
complication (12-15). Nonetheless, case reports have documented the rare 
capacity of liver transplant recipients in particular to spontaneously develop full 
peripheral blood chimerism without GVHD, facilitating withdrawal of 
immunosuppressive medications without rejection (16, 17). Large cohort studies 
have also shown that, for still poorly understood reasons, multivisceral transplant 
recipients whose allografts include hepatic tissue have improved outcomes 
compared to those who do not undergo concurrent liver transplantation (18-20). 
In the absence of donor bone marrow infusion, human studies of post-transplant 
macrochimerism in the absence of GVHD are minimal (21). We hypothesized 
that the large volume transfer of lymphocytes inherent to multivisceral 
transplantation (MVTx) would correlate with a higher degree of macrochimersim 
compared to intestinal transplant (iITx) or isolated liver (iLTx), and might account 
for the lower rate of severe intestinal rejection in this population.  
 
We assessed lineage chimerism using a refined flow cytometric technique and 
examined the effect of increasing the donor antigenic and lymphoid load by 
comparing recipients of MVTx versus iITx and iLTx.   
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Materials and Methods 
 
Recruitment of Subjects, Blood Collection and Processing 
Approval was obtained from the Columbia University Institutional Review Board 
(IRB# AAAJ5056). Subjects were recruited by our center’s transplant biobank 
(Columbia Center for Translational Immunology, Columbia University Medical 
Center). All subjects or legal guardians provided their written, informed consent.  
The patients enrolled into this study received either a small intestine in isolation 
or as part of a multivisceral allograft. Multivisceral allografts included the liver, 
stomach, duodenum, pancreas and small intestine with or without colon and 
required recipient splenectomy at the time of the surgery.  The nine intestinal 
transplant recipients received anti-thymocyte globulins (ATG) as induction 
followed by maintenance therapy that included tacrolimus and steroids. One of 
the MVTx recipients was highly sensitized before transplantation and additionally 
received prophylactic plasmapheresis, polyclonal immunoglobulin and rituximab. 
Blood was drawn and prospectively collected from iITx and MVTx, weekly for the 
first two months and then progressively less often, whenever possible, until 1 
year post-transplant.  All patients underwent pre- and post-transplant serum 
testing (on a weekly basis the first month and then progressively spaced out) for 
class I and II donor-specific antibodies (DSA) by Luminex ®SA (Luminex 
LABScreen® Single Antigen, One Lambda Inc., CA, USA). All beads showing a 
normalized Mean Fluorescence Intensity > 1000 were considered positive. 
Protocol biopsies were obtained in the initial post-transplant course in addition to 
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biopsies for symptoms. Protocol biopsies were usually performed 2 times per 
week for the first month, 1 time per week for the following 2 months, and once a 
month until one year post-transplant. The pathologic scoring scheme used to 
grade acute cellular rejection at our institution relies mostly on the apoptotic body 
count, as previously reported (22) . Antibody-mediated rejection (AMR) was 
characterized by the following features: presence of diffuse C4d capillary staining 
in the lamina propria, associated with vascular changes and circulating DSA. 
Mixed rejection referred to the co-existence of ACR and AMR. 
 
Ten iLTx recipients were retrospectively enrolled in the study to act as a control 
group for comparing donor chimerism among recipients of highly lymphoid 
allografts. The immunosuppressive regimen in iLTx included no (n=8) or 
basiliximab (n=2) induction therapy followed by a combination of steroids, 
tacrolimus and mycophenolic acid. Blood samples were drawn from living liver 
donors and their respective liver recipients just prior to transplantation and from 
hepatic transplant recipients at roughly 7, 14, 30, 60, 180, 270 and 365 days 
post-transplant, whenever possible.  
 
HLA Typing, Antibody Selection and Cellular Staining 
We screened candidate monoclonal HLA class I allele-specific antibodies (mAb) 
for the ability to discriminate donor and pre-transplant recipient cells, based on 
molecular HLA typing information. mAb were purchased from OneLambda or BD 
Biosciences. Each mAb was quality control tested for specificity. Those that 
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readily distinguished donor from the pretransplant recipient peripheral blood 
mononuclear cells (PBMCs) were used in the corresponding post-transplant 
chimerism assay(s) (Table S1). Just prior to staining, cryopreserved and thawed 
PBMCs were incubated with human AB serum to block nonspecific binding to Fc 
receptors. The following anti-human antibodies were used: CD3-Percp-Cy5 
(SP34-2), CD8-APC-Cy7 (SK1), CD45-V500 (HI30), CD33-AF700 (WM53), 
CD11c-PE-Cy5 (B-ly6), CD14-Pacific Blue (M5E2), HLA-ABC-APC (G46-2.6), 
and HLA-A2-PE (BB7.2) from BD Pharmingen; CD4-AF700 (OKT4), and CD19-
Pacific Blue or -PE (HIB19) from BioLegend; HLA A2, A28-FITC or-biotin 
(BIH0037), HLA A30, A31-biotin (BIH0087), HLA A9-FITC or –biotin (FH0964), 
HLA A11-biotin (BIH0084), HLA 25, 26-biotin (BIH0048), HLA A29-biotin 
(BIH0155), HLA B8-FITC or –biotin (FH0536A), HLA B7, B27-biotin (BIH1453), 
HLA B12-biotin (BIH0066), HLA B13-biotin (BIH0261), HLA Bw4-biotin (BIH007) 
from One Lambda.  
Leukocytes were identified with anti-CD45. Lymphoid lineage panels included 
anti-CD3, CD4, CD8, and CD19. Myeloid lineage panels included anti-CD33, 
CD11c, and CD14. Both lineage panels included pan-HLA-ABC antibody in 
addition to anti-donor and/or anti-recipient HLA mAbs specifically selected to 
distinguish between a particular donor-recipient pair. Just prior to FCM analysis, 
DAPI stain was added to each FACS tube to allow for exclusion of dead cells.  
 
Sensitivity Assays 
Once an HLA allele group-specific antibody was selected to distinguish donor 
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and recipient cells, cell dilution assays were carried out to test its sensitivity for 
detecting known percentages of donor PBMCs within a sample of liver transplant 
recipient PBMCs. Selected HLA class I antibodies were tested on artificial 
mixtures of known ratios of donor and recipient pre-transplant cells.  Whenever 
sufficient cell numbers were available, known donor concentrations ranged from 
0.1 to 50%; in other cases, serial dilutions ranged from 1.0 to 50%. The dilution 
assays were carried out with an anti-recipient or anti-donor antibody. DAPI was 
added prior to data collection to gate out dead cells. 
 
Flow Cytometric Analysis and chimerism level comparison across different 
lineages and patients 
Data was acquired using an LSR II flow cytometer (BD Biosciences) using DIVA 
software. Analysis was carried out using FlowJo software (TreeStar, Inc, 
Ashland, OR). CD3+/CD4+/CD8-, CD3+/CD4-/CD8+, CD3-/CD56-/CD19+, 
CD45+/CD33+, CD45+/CD11c+ and CD45+/CD14+ populations were individually 
assessed for staining with MHC pan-class I and specific anti-donor and/or anti-
recipient antibodies. Cells that strongly stained with MHC pan-class I antibody 
and anti-donor antibody and/or not with anti-recipient antibody were determined 
to be of donor origin. For chimerism assessment in individual patients, Area 
Under the Curve (AUC) was analyzed and plotted using the software 
Mathematica (Wolfram Research, Inc, Champaign, IL). The chimerism AUC 
was the area under the curve (mathematically known as integral) in a plot of 
percentage of blood chimerism (≥ 1%) against time. The trapezoidal rule was 
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used to estimate AUC. As AUC resulted from the product of a unit of percentage 
by a unit of time, the results were given in % x days. Myeloid chimerism values 
were calculated from the sum of AUC for CD33+, CD14+ and CD11c+ lineages.  
 
Statistical Methods 
Comparisons were based on Fischer’s exact test for categorical data and the 
Mann Whitney U test for continuous data. Survival curves were analyzed using 
Kaplan-Meier analysis with log-rank testing. All statistical analyses were 
performed using GraphPad Prism Software (GraphPad Software Inc, La Jolla, 
CA). To estimate reliably the limit of quantification of donor macrochimerism, 
especially with low numbers of interrogated events, we used a one-sided Poisson 
test, which postulates that the number of donor cells, say X, given the total 
number of cells in a given lineage, say b, follows a Poisson distribution with 
mean b, where is the intensity parameter. We adopt the definition of ≤ 10 
donor cells per 1000 base cells as “noise” or the “lower limit of detection” and 
have tested the null hypothesis H0: ≤ 10/1000 base cells against the alternative 
that H1: > 10/1000 base cells (the chimerism alternative). Note that the criterion 
for rejecting H0 depends upon the base b. Table S2 provides the minimum 
number of cells, say C=C(b), such that if X ≥ C, we will reject H0 with type I error 
rate no more than =0.01 (probability of falsely declaring chimerism).     
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Results  
  
Patient characteristics and clinical outcome 
Four multivisceral (MVTx) and five isolated intestinal transplant recipients (iITx) 
were enrolled into the study (Table 1). In intestinal transplantation, more than 
50% of acute cellular rejection episodes occur within 90 days after transplant and 
there is a known correlation between the grade of rejection and probability of 
graft survival (23). Of the nine intestinal allograft recipients in our study, four 
patients experienced moderate to severe rejection episodes (n=4) within 90 days 
post-transplant after a median interval of 20.5 range: 13-39 days (Table 1). 
Among the other five patients, two experienced a mild rejection at postoperative 
day 14 and 58 and three remained rejection-free. Overall, ITx subjects who 
suffered moderate rejection received similar doses of ATG and had similar levels 
of tacrolimus exposure over the first three months, compared to those who 
experienced mild or no rejection (Table 2). Ultimately, those who experienced 
early moderate rejections were more likely to develop de novo DSA (Table 2).  
 
Over the course of follow-up (median 524 days, ranging from 132-991 days), only 
one iITx recipient had a self-limited rash from day 46 to day 54 consistent with 
biopsy-proven mild skin GVHD, which spontaneously resolved in association with 
a mild graft rejection episode. Two MVTx recipients died of post-transplant 
lymphoproliferative disorder (day 387) and fungal infection (day 343).  
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Assay Sensitivity and Accuracy 
Identification of an HLA allele-specific mAb that distinguished donor and recipient 
cells in quality control assays was a prerequisite for inclusion in the study (Table 
S1). In the quality control studies, pan-HLA-ABC Ab enabled us to identify the 
class I MHC-expressing mononuclear cells that stained appropriately or 
inappropriately negative or positive for the mAb used to identify the recipient or 
donor population. Figure 1A depicts the reactivity of two different anti-HLA-A2 
clones (BB7.2 and FH0037) with donor and recipient cells from two different 
donor-recipient pairs. In each case, the recipient and donor were HLA-A2 
positive and HLA-A2 negative, respectively. Although each clone accurately 
differentiated recipient and donor cells in iITx #5, the clone FH0037 stained both 
donor and recipient cells in iITx #4. This example illustrates the cross-reactivity of 
the currently available monoclonal anti-HLA antibodies and emphasizes the 
importance of quality control assays prior to chimerism assessment with flow 
cytometry. 
 
Dilution assays employing known concentrations of donor and recipient cells 
demonstrated that the donor cell detection threshold varied, depending on the 
particular donor/recipient pair, yet could be as low as 0.2% in some cases. 
Importantly, this flow cytometry-based approach enabled us to accurately 
distinguish between donor and recipient cells in all patients at dilutions equal to 
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or greater than 1% (Figure 1B). This finding confirmed the validity of this 
approach for studying macrochimerism. 
 
Development of donor chimerism after intestinal and multivisceral 
transplantation in the absence of significant rejection 
We used multicolor flow cytometry to prospectively monitor donor chimerism in 
lymphoid (CD3 and CD19 cells) and myeloid (CD33, CD14 and CD11c) lineages 
(e.g. Figure 2). Only the measurements of blood chimerism equal to or greater 
than 1%, assessed on an adequate number of interrogated cells for each given 
lineage, were included into the analysis (Table S2). T cell macrochimerism was 
detected in all but one (8/9) patient (Table 1). Furthermore, T cell chimerism 
peaked at a significantly higher level and was found, overall, to be more durable 
within the group that did not have episodes of moderate or severe rejection 
(Table 2, Figure 3). The peaks of both the percentage and absolute number of 
donor T-cells were significantly higher in the blood of patients who were free of 
rejection (Table 2, Figure 3A, B). Notably, the only patient (Pt6) who experienced 
a skin biopsy-proven GVHD had the highest absolute number of circulating donor 
T cells at 3 weeks post-transplant, 25 days before the occurrence of the GVHD-
related skin rash (Figure 3B).  
 
To better assess and compare chimerism levels among individual subjects who 
were not uniformly investigated on the same post-transplant days, we calculated 
the Area-Under-the-Curve (AUC) by integrating the percent donor chimerism 
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over time for each lineage (Figure 3C). Overall the extent of CD3 T cell 
chimerism was significantly greater (Median [range]: 820 [101-9098] vs 34.5 [0-
62], p<0.02) in the group with mild or no rejection than in the group that 
experienced moderate to severe rejection (Table 2). In addition, B cell and 
myeloid lineage chimerism greater than 1% was found to be present among 3/5 
and 3/5 patients free of moderate rejection respectively, whereas no B-cell or 
myeloid macrochimerism was detected in patients with significant rejection 
(Tables 1 and 2). B cell chimerism AUC tended to be higher in the absence of 
moderate rejection (Median [range]: 165 [0-9157] vs 0 [0-0], p=0.11).  
 
Lack of early T-cell chimerism following intestinal transplantation is 
associated with early moderate to severe rejection 
To investigate whether early assessment of chimerism might help to identify 
patients at greater risk of moderate rejection, we compared the clinical outcomes 
of subjects according to the peak of T cell chimerism during the first three weeks 
post-transplant. Remarkably, all subjects with peak T-cell chimerism less than 
3% experienced an early moderate rejection, whereas those with early T cell-
chimerism above 3% remained free of moderate rejection (p=0.003) (Figure 4). 
Of note, in two ITx recipients (Pt4 and Pt9), early, severe cellular rejection 
necessitated a second course of ATG. Once rejection had successfully resolved, 
T-cell chimerism transiently peaked at 2.9% (Pt4) and 3.3% (Pt9) on day 51 and 
58, respectively (Figure 3A).  
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In addition to comparing chimerism and its association with clinical events, we 
investigated the development of de novo donor-specific antibodies (DSA) in 
relation to peak chimerism. A single pre-sensitized MVTx recipient was excluded 
from this portion of the study, since he already had preformed DSA against all 7 
donor HLA-mismatches at HLA-A, B, DR and DQ loci, prior to the transplant. We 
found that a peak level of T-cell chimerism less than 3% differentiated the 
patients who developed de novo DSA from those who did not, as only the 
patients with less than 3% chimerism developed DSA (Figure 4).  
 
Rapid clearance of circulating donor cells bound by preformed DSA  
As noted above, one of the MVTx recipients was transplanted across seven high-
titer DSA (MFI>10,000) and a positive cross-match. The transplanted liver was 
expected to adsorb part of the preformed DSA and reduce their titer 
synergistically with the desensitization regimen (24, 25). However, anti-class I 
DSA remained at a very high titer during the post-transplant course (Figure 5A), 
and an early mixed and moderate rejection occurred at day 21. Donor cells were 
readily detected in the blood at day 7 post-transplant (Figure 5B), but were barely 
detectable one week later and became undetectable shortly thereafter, in 
contrast to the other MVTx recipients who all had sustained T-cell chimerism 
(Figure 6). Donor chimerism was not only very short-lived but was also 
associated with an unusual flow cytometric pattern: post-transplant donor T and 
B cells displayed lower levels of HLA class I by flow cytometry than recipient cells 
(Figure 5B and C), whereas pre-transplant cells did not differ in HLA class I 
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staining (Figure 5C). We reasoned that in vivo binding of DSA to circulating 
donor cells might result in reduced in vitro access of the anti-class I antibody to 
donor HLA molecules. To test this hypothesis, we incubated donor and recipient 
pre-transplant cells with pre-transplant recipient serum and stained with an anti-
class I antibody (Figure 5D). Donor, but not recipient cells incubated with 
recipient serum displayed decreased detectable HLA class I levels. This finding 
suggests that DSA competed with anti-class I antibody for binding to donor HLA 
molecules. To demonstrate more directly that DSA were bound to circulating 
donor T cells, PBMCs collected at POD7 were stained with an anti-human IgG 
antibody (Figure 5E). The Donor/Recipient mean fluorescent intensity (MFI) ratio 
was 2.9 fold greater with the anti-human IgG staining compared to the 
fluorescence-minus-one control, demonstrating in vivo binding of donor cells by 
anti-donor antibody.  
 
Multivisceral transplantation is associated with multilineage and sustained 
chimerism 
Multivisceral transplantation and combined liver-intestine transplantation have 
been associated with both a greater incidence of GVHD (11, 26) and a reduced 
rate of severe rejection compared with isolated intestinal transplantation (18-20). 
We hypothesized that the higher donor lymphoid load contained within a 
multivisceral allograft might induce greater donor chimerism. To avoid 
confounding factors in a size-limited cohort, we investigated a homogenous 
population that included only the 7 non pre-sensitized patients who were free of 
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GVHD (Figure 6). The median duration [range] of T cell macrochimerism was 
242 [127-378] and 35.5 [0-58] days in the MVTx and iITx recipients, respectively 
(p=0.057). B cell macrochimerism was also detected in the two MVTx recipients 
and in one of the 4 iITx recipients. Overall, CD3+ T (median [range]: 1073 [702-
9098] vs 56.5 [0-101], p=0.057) and CD19+ B (median [range]: 1675 [0-9157] vs 
0 [0-165], p=0.24) cell chimerism AUC tended to be greater in the MVTx than in 
the iITx recipients (Figure 6), reflecting mostly more sustained levels of mixed 
chimerism, but fell short of statistical significance in this limited population. 
 
To further investigate the role of the liver allograft in the development of post-
transplant chimerism, 10 isolated liver transplant recipients were also studied. 
Although 6/7 of the non-sensitized GVHD-free intestinal transplant recipients 
exhibited T cell macrochimerism, only 3 out of 10 iLTx recipients had T cell 
macrochimerism (Fischer’s exact test, p<0.05). T- (p<0.01) and B-cell (p<0.05) 
chimerism AUC were significantly lower in iLTx recipients than in the MVTx 
recipients (Figure 6). Finally, all three MVTx and three of 10 iLTx recipients had 
chimerism > 1% in at least one myeloid lineage, while myeloid chimerism was 
never detected in recipients of intestinal allografts without a liver (Table 1, Figure 
6).  
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Discussion 
 Our study is the first to prospectively assess multilineage chimerism with 
multicolor flow-cytometry and to study its clinical significance among intestinal 
transplant recipients. Mixed chimerism after intestinal transplantation, mostly in T 
cell lineages, has been previously assessed in cross-sectional studies using 
molecular techniques (27, 28) or, less often, four-color flow-cytometry (26, 29), 
and was repeatedly correlated with the development of GVHD (26, 27). T-cell 
macrochimerism has also been reported sporadically in a few patients who are 
free of GVHD (26, 27).  
 
One of the key findings of our study is that the occurrence of T-cell mixed 
chimerism (≥1%) after intestinal transplantation (8/9) was far more frequent than 
the occurrence of GVHD (1/9). This finding is in contrast to most previous 
studies, in which donor chimerism has been used as a biomarker for the 
development of GVHD. Some authors have gone as far as to propose that 
chimerism greater than 20% is highly specific for GVHD (28, 30). Nevertheless, 
we found that lymphoid lineage chimerism exceeding 40% occurred in a MVTx 
recipient without any signs of GVHD, providing the first documented evidence 
that chimerism of this magnitude can be achieved in multivisceral graft recipients 
without irradiation or bone marrow infusion and remain present for greater than 
one year even in the absence of pathology. Moreover, our data suggest that 
absolute donor T cell count, rather than percentage of T-cell chimerism, might be 
a more accurate predictor of GVHD.  
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Multivisceral transplantation is known to elicit a protective effect against intestinal 
graft rejection (18, 19, 24) but to increase the risk of GVHD following intestinal 
transplantation (11, 26). Adult liver and small intestine, each weighing 
approximately 1.5 to 2 kg, are estimated to contain 1x1010 and 1.2x1010 
lymphocytes, respectively (31, 32), without taking into account organ-associated 
lymph nodes. We hypothesized that, as a consequence of the greater donor 
lymphoid mass carried by the allograft, a higher level of mixed chimerism would 
be observed in MVTx compared to iITx transplant recipients. We compared 
patients with and without moderate to severe rejection during the first 3 months 
post-transplant and found that the latter had higher and more sustained mixed 
chimerism. We considered the possibility that the lower chimerism in rejecting 
patients might simply reflect a less dramatic reduction of recipient lymphoid mass 
(Figure S1). However, there are two arguments that definitively support the 
existence of a true increase in chimerism in the patients who were free of 
rejection. First, absolute counts demonstrated a higher number of circulating 
donor T cells in the absence of significant rejection. Second, greater B-cell 
chimerism was also observed in this group, although ATG has no effect on B-cell 
number (33).  
 
We believe that the presence of blood chimerism after intestinal transplantation is 
determined by the balance between Host-vs-Graft (HvG) and Graft-vs-Host 
(GvH) responses. At one extreme, a deficient immune system in the recipient, 
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either related to young age, or intestinal atresia-associated immune deficiency or 
splenectomy (11, 26), has been associated with a higher risk of GVHD. Our 
study also suggests that the HvG response may influence the level of GVHD-free 
chimerism. Spleen removal reduces the recipient lymphoid compartment in MVTx 
recipients and may thereby further decrease the HvG response and promote the 
recirculation of donor cells. The occurrence of delayed peak chimerism in two 
subjects after the successful treatment of a moderate rejection episode suggests 
that control of HvG responses allowed mixed chimerism to develop. Interestingly, 
the sole patient who remained free of significant early rejection despite a lack of 
ATG-induced lymphodepletion (Figure S1) experienced GVHD in association 
with high-level donor chimerism. Our results are consistent with the possibility 
that a strong GvH response can also promote donor cell engraftment by 
counterbalancing the HvG response (16). The association between 
microchimerism and lack of rejection after SOT has been intensely controversial, 
reflecting the complexity of a chicken and egg situation in which it is unclear 
which leads to the other (34). However, our study focused on macrochimerism, 
which has been associated with the induction of both central (35) and peripheral 
(36) tolerance mechanisms. We thus propose that sustained macrochimerism in 
multivisceral transplant recipients may further reduce HvG T and B-cell 
responses. Combined with recipient spleen removal and the immunoprotective 
effect of the liver allograft (37), macrochimerism may contribute to lower rates of 
rejection in MVTx recipients.   
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The lack of recipient T-cell depletion may account for the low incidence of T-cell 
chimerism that we observed in iLTx recipients, none of whom underwent ATG 
induction therapy. In addition, the lower incidence of GVHD after iLTx (0.1 to 2%) 
(38) compared to intestinal transplantation (4.5 to 9%) (11, 26) may also reflect 
differences between mature lymphoid cell populations contained within intestinal 
versus liver allografts. Conventional T cells contained within gut-associated 
lymphoid tissue (GALT) and intestinal lamina propria (39), rather than the more 
numerous, unconventional intestinal IEL and liver lymphoid cells, known to poorly 
recirculate in the blood (31, 39), may account for the early wave of T-cell 
chimerism among intestinal allograft recipients, mainly driven by GvH reactivity. 
Lymphohematopoietic GvH Responses (LGVHR), which are GvH reactions 
confined to the lymphohematopoietic system that spare the epithelial GVHD 
target organs, make hematopoietic “space” that promotes multilineage chimerism 
in experimental models (40). 
 
Human liver and small bowel also host hematopoietic stem cells and lineage-
committed hematopoietic progenitors, which have been implicated in late and 
sustained mixed chimerism after liver transplantation (41). Strikingly, a few cases 
of donor-derived multilineage long-term hematopoiesis without GVHD have been 
reported after isolated liver (16, 17) and combined liver and intestinal (42) 
transplantation. Consistently, hematopoietic stem cells isolated from the liver 
successfully reconstitute hematopoiesis in lethally irradiated animals (43). 
However, liver and intestinal hematopoietic progenitors may differ in their 
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multilineage differentiation potential. Although liver hematopoietic stem cells can 
give rise to multiple lineages, including lymphoid (44) and myeloid (45) cells, 
human gut-derived progenitors cells are almost exclusively lymphoid (CD7 
positive) (46) and therefore only able to generate T cells (47). Consistent with 
this observation, in contrast to liver and multivisceral recipients, liver-free 
intestinal transplant recipients never displayed myeloid macrochimerism in our 
study. Likewise, chimerism among liver-free allograft recipients lasted for a 
shorter period of time post-operatively compared to subjects whose transplants 
included hepatic tissue.  
 
Finally, the study of chimerism in a highly sensitized MVTx recipient 
demonstrated that preformed high titer DSA could bind in vivo to circulating 
donor cells (in vivo flow-crossmatch), possibly accelerating their clearance. This 
finding explains the protective effect of positive crossmatch against GVHD after 
intestinal transplantation (26) and is consistent with the growing recognition that 
DSA increases the risk of graft failure after bone marrow transplantation (48). In 
addition, this finding provides further evidence that anti-HLA sensitization may be 
a major hurdle for inducing tolerance through mixed chimerism, similar to 
observations in the mouse model (49). 
 
Our study is limited by the small sample size, underscoring the need for a 
prospective multi-center study to confirm and verify our findings. Should larger 
studies reproduce our findings, routine monitoring of mixed chimerism may 
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become a very useful tool for treatment tailoring after intestinal and multivisceral 
transplantation. These studies might also pave the way for pilot protocols 
combining bone marrow and intestinal transplantation, such as those established 
in rodents, to promote donor-specific tolerance (50). 
 
In summary, GVHD-free mixed T-cell chimerism occurs as a general rule after 
intestinal transplantation in the absence of an overwhelming cellular and/or 
humoral HvG response. Conversely, its absence may indicate under-
immunosuppression and an increased risk of moderate to severe rejection and 
development of de novo DSA. The association between macrochimerism and 
lack of significant rejection suggests that the greater chimerism observed after 
MVTx might contribute, at least in part, to the lower incidence of rejection among 
that population of transplant recipients.  
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Figure Legends: 
 
Figure 1: Assay Sensitivity and Accuracy 
(A):  Dot plots demonstrating variable cross-reactivity of anti-HLA-A2 mAbs 
between two separate iITx donor / recipient pairs. (B):  Summary of findings 
regarding the sensitivity of anti-donor and anti-recipient antibodies for detecting 
the chimeric cell population in the iLTx population. Each color represents a 
different subject. Each dot represents a different dilution.  
 
Figure 2: Sustained multilineage chimerism in a multivisceral transplant 
recipient 
Representative plots showing how donor and recipient cells were differentiated 
with a combination of donor- and recipient-specific antibodies (MVTx recipient 
#1). CD3+/CD4+ CD3+/CD8+, CD45+/CD19+, CD45+/CD33+, CD45+/CD11c+ 
and CD45+/CD14+ populations were individually assessed for staining with anti-
donor (HLA-A2) and anti-recipient (HLA-A9) antibodies. 
Abbreviations: Post-Tx, post-transplantation; Pre-Tx, pre-transplantation; wks, 
weeks 
 
Figure 3: Analysis of T-cell (CD3+) chimerism over time in MVTx and iITx 
recipients according to the occurrence of an early moderate to severe 
rejection episode. 
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(A) Patients free of significant rejection had higher T cell chimerism both in 
frequency and absolute number. Circles and triangles indicate MVTx (Pts 1, 3, 7 
and 10) and iITx (Pts 2, 4, 5, 6, 9) recipients, respectively (B) The early (within 3 
weeks) peak of T-cell chimerism was significantly higher in the patients without 
moderate rejection. Pt6 (red dot), who experienced skin GVHD episode from day 
46 to 54, displayed the highest absolute count of circulating donor T cells at 3 
weeks. (C): Calculation of overall chimerism (Area Under Curve) by integrating 
the donor chimerism frequency over time.  
Abbreviations: Pt, patient; wks, weeks 
 
Figure 4: Low early chimerism associated with the development of 
significant rejection 
(A): Freedom from early (<90 days) moderate to severe rejection (left) and de 
novo DSA (right) after intestinal transplantation according to the peak of donor T-
cell chimerism within 3 weeks post-transplant.  
 
Figure 5: Early clearance of DSA-bound circulating donor cells. 
(A,B): Post-transplant persistence of preformed high titer anti-class I DSA in a 
sensitized multiviceral transplant recipient (A), was associated with early 
disappearance of T-cell chimerism (B). (C): In this highly sensitized patient 
(Pt10), post-transplant, but not pre-transplant, donor cells display a lower level of 
detectable HLA class I, when compared to recipient cells. In contrast, post-
transplant donor and recipient cells have comparable HLA class I expression in 
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non-sensitized patients (representative staining from Pt7). (D): Incubation with 
pre-transplant Pt10 serum decreases the HLA-class I staining on donor, yet not 
on recipient, pre-transplant cells. (E): The positive anti-human IgG staining on the 
circulating donor cells showed that they had been bound in vivo by DSA.  
 
Figure 6: Higher GVHD-free blood chimerism in non-sensitized MVTx 
compared to iLTx and iITx recipients.  
 
Figure S1: Absolute lymphocyte count.  
Early ATG-induced lymphodepletion and lymphocyte reconstitution until 1 year 
after transplantation were assessed for each group, according to the rejection 
status. Circles and triangles indicate MVTx (Pts 1, 3, 7 and 10) and iITx (Pts 2, 4, 
5, 6, 9) recipients, respectively.  
 
Table 1: Individual clinical characteristics and chimerism data in intestinal 
transplant recipients 
Abbreviations: ATG, anti-thymoglobulin; Don, donor; DSA, donor-specific 
antibody; iITx, isolated intestinal transplantation; IVIG, intra-venous 
immunoglobulin; MVTx, multivisceral transplantation; PE, plasma exchanges; 
Rec, recipient; Tx, transplantation; yrs, years. 
 
Table 2: Clinical characteristics and chimerism data in intestinal transplant 
recipients with and without early (<3 months) moderate to severe rejection 
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Abbreviations: ATG, anti-thymoglobulin; AUC, Area Under the Curve; CDC, 
complement-dependent cytotoxicity; chim., chimerism; DSA, donor-specific 
antibody; GVHD, graft-vs-host disease; mo, months; PRA, panel reactive 
antibody; Pre-Tx, pre-transplantation; SPA, solid-phase assay; T0, trough levels 
 
Table S1: HLA class I typing and anti-HLA antibodies used to distinguish 
donor from recipient cells in intestinal transplant recipients 
HLA-A9 (*) and HLA-B12 (**) are broad antigen HLA serotypes that encompass 
the HLA-A23 / HLA-A24 serotypes, and the HLA-B44 / HLA-B45 serotypes, 
respectively. 
Abbreviations: ITx, intestinal transplant recipient; LTx, liver transplant recipient 
 
Table S2: Minimum number of donor cells that should be detected C(b), 
depending upon the number of interrogated events (b), to ensure the 
presence of a true macrochimerism (frequency of donor cells ≥ 1%) in a 
given lineage.   
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Table 1 
 
Pt# 
 
Rec. 
Age 
(yrs) 
Don. 
Age 
(yrs) 
Indication 
for 
iITx/MVTx 
Type of Tx Post-Transplant Outcome 
and Anti-Rejection 
Therapies (within 90 days) 
Peak of 
CD3+ T cell 
macrochim. 
(%) 
Peak of 
myeloid 
macrochim. 
(%) 
1 53 6 Gardner’s 
Syndrome 
MVTx, including 
colon 
No rejection, no DSA 43.1   CD33: 7.1 
CD14: 0 
CD11c: 0 
2 47 48 Short gut 
syndrome 
iITx Early moderate rejection 
Steroid IV pulses and oral 
taper 
 
0  CD33: 0 
CD14: 0 
CD11c: 0 
3 17 21 Pseudo-
obstruction 
MVTx No rejection, no DSA 8.2 CD33: 0 
CD14: 1.4 
CD11c: 0 
4 6 2 Dysmotility iITx Early moderate rejection  
Mixed rejection (de novo 
DSA) 
Steroid IV pulses and oral 
taper, ATG, rituximab, IVIG 
 
2.9  CD33: 0 
CD14: 0 
CD11c: 0 
5 27 13 Short gut 
syndrome 
iITx No rejection, no DSA 6.6 CD33: 0 
CD14: 0 
CD11c: 0 
6 3 3 Short gut 
syndrome 
iITx Self-limited skin GVHD 
Mild rejection, no DSA 
Steroid IV pulses and oral 
taper 
 
23.9 CD33: 0 
CD14: 0 
CD11c: 0 
7 53 44 Entire porto-
mesenteric 
system 
thrombosis 
 
MVTx Mild rejection, No DSA 
Steroid IV pulses and oral 
taper 
16.3 CD33: 0 
CD14: 0 
CD11c: 12.6 
9 2 1 Short gut 
syndrome 
iITx Early moderate rejection  
Mixed rejection (de novo 
DSA) 
Steroid IV pulses and oral 
taper, ATG, rituximab, IVIG, 
PE 
3.3 CD33: 0 
CD14: 0 
CD11c: 0 
10 32 2 Extensive 
porto-
mesenteric 
system 
thrombosis 
MVTx Early moderate rejection  
Mixed rejection (preformed 
DSA) 
Steroid IV pulses and oral 
taper, ATG, rituximab, IVIG, 
PE 
2.2 CD33: 0 
CD14: 0 
CD11c: 0 
 
 
 34 
Table 2 
 Moderate to 
severe 
rejection 
(n=4) 
Mild or no 
rejection 
(n=5) 
p value 
Recipient Age 21.8  21.5 30.6  22.2 ns 
Donor Age 13.3 23.2 17.4  16.4 ns 
Multivisceral Allograft 1/4 3/5 ns 
Pre-Tx PRA>0 (CDC) 1/4 0/5 ns 
Pre-Tx DSA (SPA) 1/4 1/5 ns 
Cumulative ATG induction dose (mg/kg) 8.0  1.5 9.9  1.4 ns 
Mean tacrolimus T0 levels 0-3 mo (ng/mL) 15.3  2.1 16.8  3.2 ns 
De novo DSA (SPA) 3/4 0/5 p<0.05 
GVHD 0/4 1/5 ns 
T-cell macrochimerism  3/4 5/5 ns 
B-cell macrochimerism  1/4 3/5 ns 
Myeloid macrochimerism  0/4 3/5 ns 
Median [range] duration of T-cell 
macrochimerism (days) 
28.5 [0-58] 127 [21-378] p=0.19 
Median [range] peak of CD3 chim. (days x %) 2.6 [0-3.3] 16.3 [6.6-43.1] p<0.02 
Median [range] peak of CD4 chim. (days x %) 4.8 [0-7.8] 10.3 [8.3-29.4] p<0.02 
Median [range] peak of CD8 chim. (days x %) 1.8 [0-3.7] 21.4 [6.8-54.8] p<0.02 
Median [range] peak of CD19 chim. (days x %) 0 [0-0] 8.8 [0-61] p=0.11 
Median [range] peak of CD33 chim. (days x %) 0 [0-0] 0 [0-7.1] ns 
Median [range] peak of CD11c chim. (days x %) 0 [0-0] 0 [0-12.6] ns 
Median [range] peak of CD14 chim. (days x %) 0 [0-0] 0 [0-1.4] ns 
Median [range] CD3 chim. AUC (days x %) 34.5 [0-62] 820 [101-9098] p<0.02 
Median [range] CD4 chim. AUC (days x %) 69.5 [0-225] 750 [142-7653] p<0.05 
Median [range] CD8 chim. AUC (days x %) 24.7 [0-69] 921 [105-8109] p<0.02 
Median [range] CD19 chim. AUC (days x %) 0 [0-0] 165 [0-9157] ns 
Median [range] Myeloid chim. AUC (days x %) 0 [0-0] 202 [0-731] ns 
Median follow-up (days [range]) 415 [132-941] 524 [343-991] ns 
Death  0/4 2/5 ns 
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Table S1 
Pt# Recipient 
HLA I type 
Donor 
HLA I type 
HLA I allele-specific mAbs  
selected for chimerism study  
ITx#1 A11 / A24 
B7 / B75 
A02 / A11 
B7 / B51 
anti-HLA A9* (clone FH0964)  
anti-HLA A2 (clone FH0037) 
ITx#2 A24 / A30 
B35 / B44 
A30 / A31 
B42 / B65 
anti-HLA A9* (clone FH0964)  
 
ITx#3 A24 / A68 
B45 / B71 
Bw6 / Bw6 
A30 / A33 
B53 / B57 
Bw4 / Bw4 
anti-HLA A9* (clone FH0964)  
anti-HLA Bw4 (clone BIH007) 
ITx#4 A02 / A30 
B42 / B53 
A03 / A68 
B39 / B57 
anti-HLA A2 (clone BB7.2)  
 
ITx#5 A02 / A33 
B14 / B51 
A11 / A32 
B8 / B18 
anti-HLA A2 (clone FH0037)  
anti-HLA A11 (clone BIH0084) 
ITx#6 A02 / A30 
B39 / B51 
A30 / A74 
B42 / B53 
anti-HLA A2 (clone FH0037)  
 
ITx#7 A02 / A03 
B07 / B44 
A01 / A02 
B08 / B44 
anti-HLA B8 (clone FH0536A) 
ITx#9 A11 / A23 
B18 / B44 
A11 / A31 
B07 / B44 
anti-HLA A9* (clone FH0964)  
anti-HLA A30/31 (clone BIH0087) 
ITx#10 A30 / A- 
B08 / B13 
A03 / A66 
B44 / B58 
anti-HLA B8 (clone FH0536A) 
LTx#1 A11 / A02 
B35 / B75 
A11 / A32 
B45 / B75 
anti-HLA A2 (clone BB7.2)  
 
LTx#2 A02 / A- 
B07 / B53 
A2 / A30 
B53 / B58 
anti-HLA A30/31 (clone BIH0087) 
LTx#3 A01 / A02 
B07 / B27 
A02 / A03 
B27 / B44 
anti-HLA B12** (clone BIH0066) 
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LTx#4 A23 / A30 
B15 / B35 
A30 / A- 
B35 / B- 
anti-HLA A9* (clone FH0964)  
 
LTx#5 A01 / A30 
B13 / B- 
A25 / A33 
B18 / B- 
anti-HLA B13 (clone BIH0261) 
LTx#6 A11 / A30 
B18 / B55 
Bw6 / Bw- 
A11 / A68 
B49 / B55 
Bw4 / Bw6 
anti-HLA Bw4 (clone BIH007) 
LTx#7 A02 / A26 
B18 / B35 
A29 / A68 
B49 / B55 
anti-HLA A29 (clone BIH0155) 
LTx#8 A01 / A11 
B35 / B55 
A26 / A30 
B35 / B37 
anti-HLA A30/31 (clone BIH0087) 
LTx#9 A02 / A- 
B15 / B44 
A03 / A11 
B07 / B08 
anti-HLA B8 (clone FH0536A) 
LTx#10 A26 / A29 
B14 / B65 
A24 / A31 
B35 / B- 
anti-HLA A25/26 (clone BIH0048) 
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Table S2 
 
 
 
Number of cells in 
the interrogated 
population (b) 
Poisson mean C(b) C(b)/b (%) 
150 1.5 6 4 
500 5 12 2.4 
1000 10 19 1.9 
5,000 50 68 1.36 
10,000 100 125 1.25 
50,000 500 554 1.108 
 
 
